Skip to main content
Scientific Data logoLink to Scientific Data
. 2019 Jul 5;6:116. doi: 10.1038/s41597-019-0117-3

Metagenomics and transcriptomics data from human colorectal cancer

Tina Visnovska 1,2,, Patrick J Biggs 3, Sebastian Schmeier 1, Frank A Frizelle 4, Rachel V Purcell 4
PMCID: PMC6611873  PMID: 31278253

Abstract

Colorectal cancer is a heterogenous and mostly sporadic disease, the development of which is associated with microbial dysbiosis. Recent advances in subtype classification have successfully stratified the disease using molecular profiling. To understand potential relationships between molecular mechanisms differentiating the subtypes of colorectal cancer and composition of gut microbial community, we classified a set of 34 tumour samples into molecular subtypes using RNA-sequencing gene expression profiles and determined relative abundances of bacterial taxonomic groups. To identify bacterial community composition, 16S rRNA amplicon metabarcoding was used as well as whole genome metagenomics of the non-human part of RNA-sequencing data. The generated data expands the collection of the data sources related to the disease and connects molecular aspects of the cancer with environmental impact of microbial community.

Subject terms: Data publication and archiving, Colorectal cancer, Cancer genomics


Design Type(s) transcription profiling design • disease analysis objective
Measurement Type(s) transcription profiling assay • rRNA 16S
Technology Type(s) RNA sequencing • amplicon sequencing
Factor Type(s) sex
Sample Characteristic(s) human gut metagenome • Homo sapiens • colorectum

Machine-accessible metadata file describing the reported data (ISA-Tab format)

Background & Summary

Colorectal cancer (CRC) is one of the most common types of cancer worldwide, in terms of both incidence and mortality1. Most cases of CRC are sporadic with no known genetic link. Environmental factors are therefore likely to play a critical role in the development of the disease, and a key characteristic of the colon is that it houses the largest proportion of the human microbiome, suggesting that this might play a role in causing CRC. Recent data points to the importance of the microbial communities in the gut, the microbiome, and possible links to the development of CRC25. If this is the case, understanding the role of the microbiome in CRC will have profound effects on cancer rates, since it is potentially relatively easily to manipulate, using diet, pre- and probiotics and faecal transplants69. However, despite the intense interest in the field and increasing evidence pointing to a role for the microbiome in CRC, convincing connections with clinical parameters and outcome are rarely seen.

CRC is a highly heterogeneous disease, with varying clinical outcomes, response to therapy, and morphological features, and molecular subtyping systems based on CpG-island methylation, microsatellite instability and gene mutations have shown strong associations with outcome and response to therapy in CRC1013.

Contrary to other microbiome studies, where CRC is treated as a single disease entity, we focused on the association between Consensus Molecular Subtypes (CMS) of colorectal cancer and gut microbiome patterns in the accompanying primary publication14. We stratified a set of CRC tumour samples into CMS according to their gene expression profiles15 and assessed differences in bacterial communities among CMS. The gene expression profiles were generated using RNA sequencing, and 16S rRNA metabarcoding as well as metagenomic analysis of non-human portion of the RNA sequencing data were employed for bacterial taxa quantification. We analysed the enrichment/depletion of bacterial species in one subtype compared to the other subtypes and showed enrichment of certain oral bacteria associated with CMS, which was validated using targeted quantitative PCR.

The data generated in this study combine various views of each sample as multiple different methods were used to obtain information about the samples. This allows us to study associations between the results of the particular methods. Making the raw sequencing data available together with the scripts used for data processing and analysis, we enable reuse of the data and extend the collection of the data sources related to CRC, for which the aetiology is not yet well understood.

Methods

Here, we present a more condensed version of the methods that led to data and analyses in the primary publication14. The workflow is shown in Fig. 1 and the names of the partial processes (depicted in blue in the figure) are used as titles in this section to structure the text. We make the raw sequencing data freely available in NCBI Sequence Read Archive16, and scripts together with more downstream analysis results are accessible as the Zenodo dataset17.

Fig. 1.

Fig. 1

Workflow of sample and data processing. Samples and data are shown in grey and processes highlighted in blue.

Sample collection & handling

Tumour tissue was collected from 34 patients undergoing surgery for resection of colorectal tumours. None of the patients had received chemotherapy prior to surgery, and all patients provided written, informed consent. This study was carried out with approval from the University of Otago Human Ethics Committee (ethics approval number: H16/037). Table 1 shows patient metadata for the cohort. At the time of surgery, CRC tumour cores were taken and immediately frozen in liquid nitrogen and initially stored at −80 °C. They were subsequently transferred to RNAlater ICETM (Qiagen), and equilibrated for at least 48 hours at −20 °C, prior to nucleic acid extraction. RNA and DNA were extracted from 15–20 mg each of tissue using RNEasy Plus Mini Kit (Qiagen) and DNeasy Blood and Tissue Mini Kit (Qiagen), respectively. Tissue disruption was carried out using a Retsch Mixer Mill. RNA extraction included a DNAse treatment step, and DNA extraction included overnight incubation with proteinase K, and treatment with RNAse A. Purified nucleic acids were quantified using the NanoDrop 2000c spectrophotometer (Thermo Scientific, Asheville, NC, USA), and stored at −80 °C. Nucleic acids were extracted from all tumour samples in a single batch by one operator, to avoid inter-batch variation.

Table 1.

Patient metadata for Predict colorectal cancer cohort. Gender categories M for male and F for female are used; column stage is post-operative Tumour-Node-Metastasis staging; U/C in CMS column stands for unclassified; and N/A in the side column stands for data not available.

SampleID CMS Age Gender Site Side Stage
CRC_01 CMS2 73 M Colon Left 1
CRC_02 U/C 62 F Colon Left 3
CRC_03 U/C 76 F Colon Right 2
CRC_04 CMS1 88 F Colon Right 2
CRC_05 U/C 68 F Colon Right 3
CRC_06 CMS3 63 M Colon Right 1
CRC_07 CMS2 81 F Colon Left 2
CRC_08 CMS2 74 M Colon Right 3
CRC_09 CMS1 83 F Colon Right 2
CRC_10 CMS2 81 M Colon Left 1
CRC_11 CMS3 79 F Colon Left 3
CRC_12 CMS3 79 F Colon Right 1
CRC_13 CMS2 74 F Colon Right 2
CRC_14 U/C 83 M Colon Left 2
CRC_15 CMS3 77 F Colon Right 3
CRC_16 CMS3 84 F Colon Right 3
CRC_17 U/C 77 M Colon Left 3
CRC_18 CMS2 58 M Colon Right 3
CRC_19 CMS2 77 M Colon Left 2
CRC_20 CMS3 74 M Colon Right 2
CRC_21 CMS1 75 F Colon Right 2
CRC_22 CMS3 78 F Rectum N/A 3
CRC_23 CMS2 78 F Colon Left 2
CRC_24 CMS3 45 F Colon Right 1
CRC_25 CMS1 78 F Colon Right 2
CRC_26 U/C 67 M Colon Right 3
CRC_27 CMS1 75 F Colon Right 3
CRC_28 CMS3 78 M Colon Left 1
CRC_29 CMS2 67 M Colon Right 2
CRC_30 CMS2 80 M Colon Left 2
CRC_31 CMS2 74 F Colon Right 2
CRC_32 CMS2 68 F Colon Left 4
CRC_33 CMS2 80 F Colon Right 3
CRC_34 CMS1 81 M Colon Right 3

RNA-seq

Library preparation and ribosomal RNA depletion was carried out using Illumina TruSeq stranded total RNA library prep V1 and Ribo-Zero Gold. The ribosomal RNA depletion step has potentially removed a portion of bacterial ribosomal RNA alongside of the human one, hence losing some information on bacteria. However, the same method of depletion was used on all the samples thus the potential loss would effect all of them in a similar manner. RNA sequencing was carried out using the Illumina HiSeq. 2500 V4 platform, to produce 125 bp paired end reads. Each sample library was split equally to two HiSeq lanes and the sequences from the two lanes were merged for each sample during the data processing phase.

Read mapping, Gene expression quantification, and Profile classification

Adapters and low quality segments were removed from the sequenced reads using fastq-mcf from EA Utils18 and SolexaQA++19. The cleaned reads were mapped to the GRCh38 reference human genome with STAR20 and the read count for each HAVANA annotated gene in every sample was calculated with htseq-count21. The read counts were transformed to gene expression profiles measured in transcripts-per-million (TPM) with DESeq222. The published CMS classifier15 was used to assign a molecular subtype of the disease to each sample based on the gene expression profiles (for more details see14). We identified six samples as CMS1, 13 samples as CMS2 and nine samples as CMS3. No samples were classified as CMS4, and six samples were unclassified.

Assignment of reads to bacterial taxa

A Kraken23 database was built containing all NCBI Refseq complete genomes or chromosome-level genomes (January 2017) and additional genomes of bacteria proposed to play a role in CRC, disregarding their genome status. The used bacterial genomes are listed in the files Supplementary_table_K1.xlsx (all complete and chromosome-level genomes) and Supplementary_table_K2.xlsx (of interest specifically for CRC) in the folder data/kraken of the accompanying repository. All RNA-seq reads that were not uniquely mapped to the human genome reference sequence were used as input to Kraken using this custom database for taxonomic classification per sample. Altogether, 2231 different bacterial species were detected in at least one sample and only 1.4% of the analysed reads were not assigned to any bacterial species. We visualised bacterial abundances per CRC subtype using Krona24 and the interactive plots are available at http://crc.sschmeier.com.

Differential analysis of bacterial species in CMS

We analysed the enrichment/depletion of bacterial species in one subtype compared to the other subtypes employing a strategy similar to differential expression analysis. Using edgeR25, we identified bacterial taxa with considerable abundance differences among the subtypes. For each CRC sample we used the assigned CMS subtype, the list of identified bacterial species, and the read counts corresponding to the identified species as input data. We treated all samples of a certain CMS subtype as replicates belonging to the subtype and ran differential analysis of each CMS subtype against all the other classified samples. This analysis identified bacterial species that are enriched (or depleted) in a subtype as compared to all other subtypes. For further details regarding the analysis, please refer to the primary publication14.

16S rRNA metabarcoding

Libraries containing 16S rRNA were prepared with 20 ng of DNA for each sample using primer pairs flanking the V3 and V4 hypervariable regions of the 16S rRNA gene and Illumina sequencing adaptors and barcodes were added using limited cycle PCR. Amplicon sequencing was carried out using the Illumina MiSeq platform, and paired end reads of length 250 bp were generated.

Metabarcoding data analysis

Short overlapping forward and reverse reads coming from the same fragment were joined together with FLASh26 to form sequences of the V3-V4 hypervariable 16S rRNA region. Afterwards, low quality regions were removed from the resulting fragments with SolexaQA++19. Microbiome analysis was carried out with the QIIME bioinformatics pipeline27 using the Greengenes database28 for taxonomy assignment. No further normalisation of the data was performed.

Data Records

Sequenced genomic data from both RNA-seq and 16S rRNA metabarcoding experiments are stored in the Sequence Read Archive as the study SRP11776316. Data resulting from the analyses presented here are located in the folder data of the Zenodo repository17. The data are separated into several subfolders:

  • The folder expr contains raw read counts in subfolder raw_counts, tpm-based expression profiles of all samples stored in file tpm.readyForClassifier.tsv and also file CMSclassifiedCRC.tpm.havana.tsv containing the CMS subtype classification. These files are the main outcomes of gene expression profile classifications.

  • Results of the metagenomics analysis of the non-human genomic content of RNA-seq are located in folder kraken together with two tables (Supplementary_table_K*.xlsx) containing lists of bacterial species used in this metagenomics analysis.

  • The folder 16S contains the biom file otu_table.biom resulting from the 16S rRNA metabarcoding analysis with QIIME and two partial abundance tables otu_table_sorted_*.txt.gz. The abundance tables are derived from the biom file and were used further for data visualisation in the primary publication as well as for the metagenomics method comparison.

Technical Validation

RNA-seq raw data quality

The quality of raw sequenced reads from RNA-seq experiments was assessed with FASTQC and was very good. A pair of representative per base quality plots of corresponding forward and reverse read pairs for one sample is shown in Fig. 2a). Regardless of the raw data quality, all the samples underwent routine data cleaning to ensure that no base was called with a Phred quality below 20. In Table 2, we show number of reads passing various data processing stages together with relative proportion of the reads passing two different stages.

Fig. 2.

Fig. 2

Per base quality of raw sequencing data, sample CRC_16. Output of FASTQC: (a) RNA sequencing, (b) 16S rRNA amplicon sequencing.

Table 2.

RNAseq, read counts and their ratios in various data processing stages for each sample. N/A in the CRC_14 sample stands for data not available.

sample ID sequenced read pairs (count) base quality ≥ 30 (in %) cleaned read pairs (count) cleaned in sequenced (in %) uniquely mapped read pairs (count) uniquely mapped in cleaned (in %) fragments counted in expression profiles (count) counted in mapped (in %) read pairs for meta- genomics(count) used for meta- genomics in cleaned (in %)
CRC_01 10210344 92.99 8196630 80.28 7150347 87.24 5301615 74.14 1046283 12.76
CRC_02 18195379 91.86 14099943 77.49 8953303 63.50 6339931 70.81 5146640 36.50
CRC_03 17060748 92.86 13695754 80.28 11763192 85.89 8737708 74.28 1932562 14.11
CRC_04 16113563 92.83 12984204 80.58 7771335 59.85 5515093 70.97 5212869 40.15
CRC_05 12283116 92.70 9787847 79.69 8177368 83.55 6141780 75.11 1610479 16.45
CRC_06 11889536 92.52 9444276 79.43 7689706 81.42 5485409 71.33 1754570 18.58
CRC_07 16767600 92.77 13384614 79.82 11174494 83.49 8282768 74.12 2210120 16.51
CRC_08 11692023 92.05 9148488 78.25 7211636 78.83 5370987 74.48 1936852 21.17
CRC_09 12414326 91.96 9744352 78.49 4853350 49.81 3473194 71.56 4891002 50.19
CRC_10 14196953 92.41 11216809 79.01 9659114 86.11 7307815 75.66 1557695 13.89
CRC_11 11891786 92.48 9384672 78.92 5842764 62.26 4172474 71.41 3541908 37.74
CRC_12 18376957 92.45 14448449 78.62 10438073 72.24 7535458 72.19 4010376 27.76
CRC_13 16869568 92.16 13310571 78.90 11664960 87.64 8747487 74.99 1645611 12.36
CRC_14 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
CRC_15 13680558 90.83 10481777 76.62 5713010 54.50 4035523 70.64 4768767 45.50
CRC_16 13982612 91.80 11035288 78.92 8867413 80.36 6509816 73.41 2167875 19.64
CRC_17 16873883 92.10 13306336 78.86 9959970 74.85 7181815 72.11 3346366 25.15
CRC_18 16663445 92.17 13179807 79.09 10641271 80.74 7400042 69.54 2538536 19.26
CRC_19 3518434 91.50 2721238 77.34 1258917 46.26 727030 57.75 1462321 53.74
CRC_20 13430061 91.98 10490785 78.11 1701669 16.22 1087471 63.91 8789116 83.78
CRC_21 9845344 90.87 7491472 76.09 5741211 76.64 4272125 74.41 1750261 23.36
CRC_22 15083803 91.89 11865373 78.66 10376744 87.45 7763574 74.82 1488629 12.55
CRC_23 9427192 90.64 7169010 76.05 5663964 79.01 4216223 74.44 1505046 20.99
CRC_24 11670754 90.49 8824150 75.61 6151634 69.71 4486074 72.92 2672516 30.29
CRC_25 15947939 92.42 12533528 78.59 8487630 67.72 6353442 74.86 4045898 32.28
CRC_26 14590462 91.97 11341012 77.73 9150589 80.69 6714043 73.37 2190423 19.31
CRC_27 14302258 92.33 11333614 79.24 10074723 88.89 7531937 74.76 1258891 11.11
CRC_28 11519270 91.74 9008972 78.21 7911036 87.81 5724147 72.36 1097936 12.19
CRC_29 10106322 93.12 8158472 80.73 7401313 90.72 5458587 73.75 757159 9.28
CRC_30 9323022 87.74 6502374 69.75 2697353 41.48 1445243 53.58 3805021 58.52
CRC_31 16617530 92.22 13095067 78.80 11255164 85.95 8326092 73.98 1839903 14.05
CRC_32 12418690 89.24 8994119 72.42 7557147 84.02 5644425 74.69 1436972 15.98
CRC_33 15556518 92.15 12165032 78.20 10928495 89.84 8206798 75.10 1236537 10.16
CRC_34 18455738 92.85 14793088 80.15 13219887 89.37 9995411 75.61 1573201 10.63

16S rRNA sequencing raw data quality

In Fig. 2b), we show quality of the 16S rRNA sequencing raw data for sample CRC_16. The other samples’ 16S rRNA quality plots looked similar. It can be seen that per base quality varied a little bit more along the 16S rRNA reads when compared to the RNA-seq reads, but overall the quality was very good for the 16S rRNA sequencing as well. Please note that the read length for the 16S rRNA sequencing was twice the read length of the RNA-seq, which together with differences between the used sequencing instruments explains differences in the quality plots. All the 16S rRNA samples underwent routine data cleaning to ensure that no base was called with a Phred quality below 20. In Table 3, we show number of reads passing various data processing stages together with relative proportion of the reads passing two different stages.

Table 3.

16S rRNA metabarcoding, read counts and their ratios in various data processing stages for each sample.

sampleID sequenced read pairs (count) base quality ≥ 30 (in %) cleaned fragments (count) cleaned in sequenced (in %)
CRC_01 333335 89.75 176823 53.05
CRC_02 238221 92.15 126462 53.09
CRC_03 356650 91.98 187474 52.57
CRC_04 307676 92.35 165991 53.95
CRC_05 261798 93.33 148547 56.74
CRC_06 122630 92.36 67416 54.98
CRC_07 175589 94.39 104310 59.41
CRC_08 210849 93.22 119255 56.56
CRC_09 238258 94.06 133700 56.12
CRC_10 233536 92.30 129813 55.59
CRC_11 291890 87.52 148406 50.84
CRC_12 173621 93.14 96744 55.72
CRC_13 204471 92.43 113588 55.55
CRC_14 255851 92.52 141822 55.43
CRC_15 254700 93.37 145899 57.28
CRC_16 210014 94.06 126141 60.06
CRC_17 197765 92.96 110784 56.02
CRC_18 161324 92.88 90441 56.06
CRC_19 147498 93.66 82425 55.88
CRC_20 235318 92.33 127779 54.30
CRC_21 169421 93.64 96627 57.03
CRC_22 249364 93.55 144146 57.81
CRC_23 171152 91.54 91281 53.33
CRC_24 102066 91.90 54880 53.77
CRC_25 334496 93.67 195656 58.49
CRC_26 265504 93.22 150713 56.76
CRC_27 69391 93.02 40037 57.70
CRC_28 137873 91.43 74333 53.91
CRC_29 176936 94.06 107348 60.67
CRC_30 202971 94.46 118078 58.17
CRC_31 220216 93.44 126807 57.58
CRC_32 108880 93.34 61688 56.66
CRC_33 219198 94.42 128793 58.76
CRC_34 305438 93.88 178759 58.53

ISA-Tab metadata file

Acknowledgements

The authors would like to thank Helen Morrin and the staff at the Cancer Society Tissue Bank, Christchurch for their enthusiasm and support for this project, the patients involved, for generously participating in this study, as well as New Zealand Genomics Limited (NZGL) for the sequencing and support in study design. Funding sources (Rachel Purcell): Maurice and Phyllis Paykel Trust, Gut Cancer Foundation (NZ), with support from the Hugh Green Foundation, Colorectal Surgical Society of Australia and New Zealand (CSSANZ).

Author Contributions

T.V. carried out bioinformatics analysis and contributed to manuscript writing. P.B. was involved in study design and data analysis. S.S. was involved in study design, bioinformatics analysis and was a contributor to manuscript preparation. F.F. was involved in study design and clinical aspects of the study. R.P. carried out nucleic acid and sequencing preparation of tumour samples and was a contributor to manuscript writing. All authors read and approved the final manuscript.

Code Availability

All the code used to process the genomic data is freely available as a part of the provided Zenodo repository17 and the code is located in the folder named scripts. The scripts folder also contains dependencies listed in the file used_packages_and_their_versions.tsv and the used parameter values listed in used_parameters.tsv. Depending on the scripts’ functionality, they are separated into various folders:

The folder rnaseq-subtype-classification contains scripts used for read mapping, gene expression quantification, and profile classification.

The folder kraken/human-unmapped contains scripts to assign reads to bacterial taxa.

The folder kraken/diff-expr-taxa contains scripts for differential analysis of bacterial species in CMS.

The folder 16S-metabarcoding contains scripts for metabarcoding data analysis.

Competing Interests

The authors declare no competing interests.

Footnotes

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

ISA-Tab metadata

is available for this paper at 10.1038/s41597-019-0117-3.

References

  • 1.Ferlay J, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in globocan 2012. International Journal of Cancer. 2015;136:E359–E386. doi: 10.1002/ijc.29210. [DOI] [PubMed] [Google Scholar]
  • 2.Ahn J, et al. Human gut microbiome and risk for colorectal cancer. Journal of the National Cancer Institute. 2013;105:1907–1911. doi: 10.1093/jnci/djt300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Marchesi JR, et al. Towards the human colorectal cancer microbiome. PLoS One. 2011;6:e20447. doi: 10.1371/journal.pone.0020447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Gao Z, Guo B, Gao R, Zhu Q, Qin H. Microbiota disbiosis is associated with colorectal cancer. Frontiers in Microbiology. 2015;6:20. doi: 10.3389/fmicb.2015.00020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Sobhani I, et al. PLoS One. 2011. Microbial dysbiosis in colorectal cancer (CRC) patients; p. e16393. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Rauch M, Lynch S. The potential for probiotic manipulation of the gastrointestinal microbiome. Current Opinion in Biotechnology. 2012;23:192–201. doi: 10.1016/j.copbio.2011.11.004. [DOI] [PubMed] [Google Scholar]
  • 7.Preidis GA, Versalovic J. Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology. 2009;136:2015–2031. doi: 10.1053/j.gastro.2009.01.072. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Gupta A, Khanna S. Fecal microbiota transplantation. The Journal of the American Medical Association. 2017;318:102–102. doi: 10.1001/jama.2017.6466. [DOI] [PubMed] [Google Scholar]
  • 9.Nakatsu G, et al. Gut mucosal microbiome across stages of colorectal carcinogenesis. Nature Communications. 2015;6:8727. doi: 10.1038/ncomms9727. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Jass J. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50:113–130. doi: 10.1111/j.1365-2559.2006.02549.x. [DOI] [PubMed] [Google Scholar]
  • 11.Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology. 2010;138:2088–2100. doi: 10.1053/j.gastro.2009.12.066. [DOI] [PubMed] [Google Scholar]
  • 12.Network CGA, et al. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330. doi: 10.1038/nature11252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Domingo E, et al. Use of multivariate analysis to suggest a new molecular classification of colorectal cancer. The Journal of Pathology. 2013;229:441–448. doi: 10.1002/path.4139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Purcell RV, Visnovska M, Biggs PJ, Schmeier S, Frizelle FA. Distinct gut microbiome patterns associate with consensus molecular subtypes of colorectal cancer. Scientific Reports. 2017;7:11590. doi: 10.1038/s41598-017-11237-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Guinney J, et al. The consensus molecular subtypes of colorectal cancer. Nature Medicine. 2015;21:1350. doi: 10.1038/nm.3967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.2017. NCBI Sequence Read Archive. SRP117763
  • 17.Schmeier S, Visnovska M, Biggs PJ, Purcell RV, Frizelle FA. 2018. Scripts and data attached to colorectal cancer study by Purcell, 2017. Zenodo. [DOI]
  • 18.Aronesty Erik. Comparison of Sequencing Utility Programs. The Open Bioinformatics Journal. 2013;7(1):1–8. doi: 10.2174/1875036201307010001. [DOI] [Google Scholar]
  • 19.Cox MP, Peterson DA, Biggs PJ. SolexaQA: At-a-glance quality assessment of Illumina second-generation sequencing data. BMC Bioinformatics. 2010;11:485. doi: 10.1186/1471-2105-11-485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15–21. doi: 10.1093/bioinformatics/bts635. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Anders S, Pyl PT, Huber W. HTSeq–a python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31:166–169. doi: 10.1093/bioinformatics/btu638. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq. 2. Genome Biology. 2014;15:550. doi: 10.1186/s13059-014-0550-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Wood DE, Salzberg SL. Kraken: ultrafast metagenomic sequence classification using exact alignments. Genome Biology. 2014;15:R46. doi: 10.1186/gb-2014-15-3-r46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Ondov BD, Bergman NH, Phillippy AM. Interactive metagenomic visualization in a web browser. BMC Bioinformatics. 2011;12:385. doi: 10.1186/1471-2105-12-385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139–140. doi: 10.1093/bioinformatics/btp616. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Magoč T, Salzberg SL. FLASH: fast length adjustment of short reads to improve genome assemblies. Bioinformatics. 2011;27:2957–2963. doi: 10.1093/bioinformatics/btr507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Caporaso JG, et al. QIIME allows analysis of high-throughput community sequencing data. Nature Methods. 2010;7:335. doi: 10.1038/nmeth.f.303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.DeSantis TZ, et al. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Applied and Environmental Microbiology. 2006;72:5069–5072. doi: 10.1128/AEM.03006-05. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Citations

  1. 2017. NCBI Sequence Read Archive. SRP117763
  2. Schmeier S, Visnovska M, Biggs PJ, Purcell RV, Frizelle FA. 2018. Scripts and data attached to colorectal cancer study by Purcell, 2017. Zenodo. [DOI]

Supplementary Materials

Data Availability Statement

All the code used to process the genomic data is freely available as a part of the provided Zenodo repository17 and the code is located in the folder named scripts. The scripts folder also contains dependencies listed in the file used_packages_and_their_versions.tsv and the used parameter values listed in used_parameters.tsv. Depending on the scripts’ functionality, they are separated into various folders:

The folder rnaseq-subtype-classification contains scripts used for read mapping, gene expression quantification, and profile classification.

The folder kraken/human-unmapped contains scripts to assign reads to bacterial taxa.

The folder kraken/diff-expr-taxa contains scripts for differential analysis of bacterial species in CMS.

The folder 16S-metabarcoding contains scripts for metabarcoding data analysis.


Articles from Scientific Data are provided here courtesy of Nature Publishing Group

RESOURCES